Corresponding data in 94 patients (81 CML-CP and 13 CML-AP) receiving NGS were 33 (35.1%; single T315I mutation), 16 (17.0%; T315I and additional noncompound mutations), 13 (13.8%; other noncompound mutations), 12 (12.8%; compound mutations), and 20 (21.3%; no BCR-ABL1 mutation). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.